Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Advanced CML or Ph+ ALL Resistant/Intolerant to Imatinib
NCT00298987Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2006
- Primary completion
- Jun 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), chronic myeloid leukemia blast phase (CML-BP), Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Bristol Myers Squibb. Started Feb 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)chronic myeloid leukemia blast phase (CML-BP)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT00298987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298987.